Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

Stopped early · Phase 2

Conditions studied: Hypertension

In brief

This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).

Key facts

Study ID

NCT00089713

Run by

Synvista Therapeutics, Inc

People needed

392

Starts

2004-03-01

Last updated by the study team

2010-02-08

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women at least 45 years of age with uncontrolled systolic hypertension measured by office cuff and by an ambulatory blood pressure monitoring device
• Willingness to be taken off any current antihypertensive treatment to be placed on hydrochlorothiazide in combination with study medication.

You may not qualify if…

• Any significant history, systemic illnesses, or medical condition(s) that could lead to difficulty complying with the protocol or that could confound interpretation of the data.

Where it is running

• Alteon Inc. — Parsippany, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.